Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20837138
Yang NY, et al. (2011) Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23, 201-12 20837138
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 no change compared to control
ephrin_A1 decrease ephrin A1 Fc
imatinib ephrin_A1 no effect upon treatment-induced decrease
dasatinib ephrin_A1 no effect upon treatment-induced decrease
PP2 ephrin_A1 augment treatment-induced decrease
ephrin_A1 HRas (human) decrease wild-type HRas
ephrin_A1 HRas (human) no effect upon treatment-induced decrease constitutively active HRas
ephrin_A1 RRas (human) no effect upon treatment-induced decrease wild-type RRas
ephrin_A1 RRas (human) no effect upon treatment-induced decrease constituvely active RRas
Mn(2+) ephrin_A1 no effect upon treatment-induced decrease
anti-integrin_alpha9beta1 ephrin_A1 no effect upon treatment-induced decrease
ephrin_A1 PIK3CA (human) inhibit treatment-induced decrease constitutively active PIK3CA
ephrin_A1 SHIP-2 (human) no effect upon treatment-induced decrease
ephrin_A1 Akt1 (human) no effect upon treatment-induced decrease wild-type Akt
ephrin_A1 Akt1 (human) inhibit treatment-induced decrease Myr Akt
ephrin_A1 PHLPP (human) no effect upon treatment-induced decrease PHLPP1siRNA no effect
ephrin_A1 PHLPP2 (human) no effect upon treatment-induced decrease PHLPP2 siRNA no effect
calyculin_A ephrin_A1 inhibit treatment-induced decrease
tautomycin ephrin_A1 inhibit treatment-induced decrease
okadaic_acid ephrin_A1 inhibit treatment-induced decrease

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
IgG increase
ephrin_A4 decrease ephrin A4 Fc
EFNA2 (human) decrease ephrin A2 siRNA increase
dasatinib ephrin_A1 no effect upon treatment-induced decrease
imatinib ephrin_A1 no effect upon treatment-induced decrease
PP2 ephrin_A1 augment treatment-induced decrease
ephrin_A1 HRas (human) no effect upon treatment-induced decrease wild-type HRas
Mn(2+) ephrin_A1 no effect upon treatment-induced decrease
anti-integrin_alpha9beta1 ephrin_A1 no effect upon treatment-induced decrease
ephrin_A1 PIK3CA (human) inhibit treatment-induced decrease constitutively active PIK3CA
ephrin_A1 SHP-2 (human) no effect upon treatment-induced decrease
ephrin_A1 Akt1 (human) inhibit treatment-induced decrease wild-type Akt
ephrin_A1 Akt1 (human) no effect upon treatment-induced decrease Myr Akt
ephrin_A1 PHLPP (human) no effect upon treatment-induced decrease PHLPP siRNA no effect
calyculin_A ephrin_A1 inhibit treatment-induced decrease
tautomycin ephrin_A1 inhibit treatment-induced decrease
okadaic_acid ephrin_A1 inhibit treatment-induced decrease

Y221-p - CRK (human)
Modsite: GGPEPGPyAQPsVNt SwissProt Entrez-Gene
Orthologous residues
CRK (human): Y221‑p, CRK iso2 (human): , CRK (mouse): Y221‑p, CRK iso3 (mouse): , CRK (rat): Y221‑p, CRK (chicken): Y222‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 increase ephrin A1 Fc
imatinib ephrin_A1 inhibit treatment-induced increase

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
EFNA2 (human) increase EFNA2 siRNA inhibits
HRas (human) decrease wild-type HRas

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
EFNA2 (human) increase EFNA2 siRNA inhibits
HRas (human) decrease wild-type HRas

T185-p - ERK2 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
EFNA2 (human) increase EFNA2 siRNA inhibits
HRas (human) decrease wild-type HRas

Y187-p - ERK2 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
ethanol increase
LY294002 decrease
rapamycin increase
PD98059 decrease
IgG increase
EFNA2 (human) increase EFNA2 siRNA inhibits
HRas (human) decrease wild-type HRas

T412-p - p70S6K (human)
Modsite: NQVFLGFtyVAPsVL SwissProt Entrez-Gene
Orthologous residues
p70S6K (human): T412‑p, p70S6K iso2 (human): T389‑p, p70S6K (mouse): T412‑p, p70S6K (rat): T412‑p, p70S6K iso2 (rat): T389‑p, p70S6K (fruit fly): T398‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ephrin_A1 decrease ephrin A1 Fc
ethanol no change compared to control
LY294002 decrease
rapamycin decrease
PD98059 increase
calyculin_A ephrin_A1 inhibit treatment-induced decrease
ephrin_A1 increase ephrin A1 Fc
imatinib ephrin_A1 inhibit treatment-induced increase

Y419-p - Src (human)
Modsite: RLIEDNEytARQGAk SwissProt Entrez-Gene
Orthologous residues
Src (human): Y419‑p, Src iso2 (human): Y425‑p, Src (mouse): Y424‑p, Src iso2 (mouse): Y418‑p, Src (rat): Y419‑p, Src (chicken): Y416‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines

T1462-p - TSC2 (human)
Modsite: GLRPRGytISDsAPs SwissProt Entrez-Gene
Orthologous residues
TSC2 (human): T1462‑p, TSC2 iso2 (human): T1419‑p, TSC2 iso3 (human): T1418‑p, TSC2 iso4 (human): T1439‑p, TSC2 (mouse): T1465‑p, TSC2 iso6 (mouse): T1443‑p, TSC2 (rat): T1466‑p, TSC2 iso2 (rat): T1423‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, colorectal cancer, colorectal carcinoma, ovarian cancer, prostate cancer
Relevant cell lines - cell types - tissues:  HT-29 (intestinal), MCF-10A (breast cell), MDA-MB-231 (breast cell), PC3 (prostate cell), SKOV-3 (ovarian), WM793
Cellular systems studied:  cell lines
Species studied:  human
Comments:  UACC 903, Lu 1205 melanoma cell lines
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ethanol increase
LY294002 decrease
rapamycin no change compared to control
PD98059 no change compared to control
ephrin_A1 decrease
dasatinib ephrin_A1 no effect upon treatment-induced decrease
imatinib ephrin_A1 no effect upon treatment-induced decrease
PP2 ephrin_A1 augment treatment-induced decrease
ephrin_A1 RRas (human) no effect upon treatment-induced decrease wild-type or constitutively active RRas
ephrin_A1 PIK3CA (human) no effect upon treatment-induced decrease constitutively active PIK3CA
calyculin_A ephrin_A1 inhibit treatment-induced decrease
tautomycin ephrin_A1 inhibit treatment-induced decrease
okadaic_acid ephrin_A1 inhibit treatment-induced decrease